WOCKPHARMA.BOWOCKPHARMA.BOBSE
Loading
EBITDA Over TimeExpanding
Percentile Rank57
3Y CAGR+16.8%
5Y CAGR+64.8%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+16.8%/yr
Annual compound
5Y CAGR
+64.8%/yr
Recent deceleration
Percentile
P57
Within normal range
vs 5Y Ago
12.1x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$3.60B+160.9%
2024$1.38B+228.6%
2023$420.00M-81.4%
2022$2.26B+258.0%
2021$-1.43B-582.5%
2020$296.40M+263.7%
2019$-181.10M+70.3%
2018$-610.70M-395.6%
2017$206.60M-95.9%
2016$5.03B-